Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 4/20 | 0.63 |
| ▸ | MC3R | P41968 | 2/20 | 0.63 |
| ▸ | PRCP | P42785 | 16/20 | 0.63 |
| ▸ | MC5R | P33032 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14090237 | 1.00 | MC4R (0.63) | MC4RMC3RPRCPMC5R | |
| SCHEMBL14204844 | 1.00 | MC4R (0.63) | MC4RMC3RPRCPMC5R | |
| SCHEMBL4591654 | 0.94 | PRCP (0.62) | MC4RMC3RPRCP | |
| SCHEMBL4577540 | 0.89 | MC4R (0.65) | MC4RMC3RPRCPMC5R | |
| SCHEMBL4577112 | 0.85 | MC4R (0.70) | MC4RMC3RPRCPMC5R | |
| SCHEMBL4591215 | 0.85 | MC4R (0.67) | MC4RMC3RPRCPMC5R | |
| SCHEMBL4591012 | 0.85 | MC4R (0.71) | MC4RMC3RPRCPMC5R | |
| SCHEMBL4577568 | 0.85 | MC4R (0.71) | MC4RMC3RPRCPMC5R | |
| SCHEMBL4575901 | 0.85 | MC4R (0.67) | MC4RMC3RPRCPMC5R | |
| SCHEMBL4592236 | 0.85 | MC4R (0.71) | MC4RMC3RPRCPMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | MERCK SHARP & DOHME CORP. | 2008-03-13 | — | — | US | claimed |
| EP-1534074-A4 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1799241-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006036770-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2006-04-06 | — | — | WO | claimed |
| US-20050288213-A1 | Combination therapy for the treatment of obesity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-12-29 | — | — | US | claimed |
| EP-1534074-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004009015-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2004-01-29 | — | — | WO | claimed |
| US-20080200376-A1 | Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction | MERCK & CO., INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | MERCK SHARP & DOHME CORP. | 2008-03-13 | — | — | US | disclosed |
| EP-1534074-A4 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1799241-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | MACNEIL TANYA | 2006-11-30 | — | — | US | disclosed |
| WO-2006036770-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20050288213-A1 | Combination therapy for the treatment of obesity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-12-29 | — | — | US | disclosed |
| EP-1534074-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004009015-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200376-A1 | Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885PRCP 773/4885 |
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | NPY4R, GPR119, GIPR | MC4R 4/4885MC3R 9/4885PRCP 474/4885 |
| US-20050288213-A1 | Combination therapy for the treatment of obesity | NPY5R, NPY4R, NPY2R | MC4R 9/4885MC3R 20/4885PRCP 463/4885 |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | GPR119, GANC, GANAB | MC4R 10/4885MC3R 67/4885PRCP 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.